Get started
Author

Misako Nagasaka

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( NRG1 ) Fusions
2025 · Tejas Patil, Jessica J. Lin, et al. · JCO Precision Oncology · 5
PDF
MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study
2022 · S.H. Ou, V. Moreno Garcia, et al. · European Journal of Cancer · 5
PDF
Abstract CT300: Taletrectinib in tyrosine kinase inhibitor (TKI)-naïve patients with ROS1+ non-small cell lung cancer (NSCLC): Updated data from TRUST-I and TRUST-II
2026 · Lyudmila Bazhenova, Jorge Nieva, et al. · Cancer Research · 2
PP01.08: Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
2026 · Sarah Waliany, Alissa J. Cooper, et al. · Journal of Thoracic Oncology · 1
Abstract CT248: Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotrectinib or taletrectinib
2026 · Geoffrey Liu, Alexander E. Drilon, et al. · Cancer Research · 1
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
2026 · Alexander Drilon, Byoung Chul Cho, et al. · The Oncologist · 1
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
2025 · Alexandria Lee, Cathleen Park, et al. · Lung Cancer Targets and Therapy · 1
Machine learning approaches to predict early cardiac immune-related adverse events in patients receiving immune checkpoint inhibitors
2026 · Michael Sayer, Peter D. Chang, et al. · Supportive Care in Cancer
PDF
PP01.09: Continued Treatment Beyond Progression with Zenocutuzumab, a HER2/HER3 Bispecific Antibody, in Patients with NRG1+ NSCLC: Analysis from the Ongoing Phase 2 eNRGy Trial
2026 · Zhaohui Liao Arter, Alison M. Schram, et al. · Journal of Thoracic Oncology
PP01.12: Efficacy and Safety of Taletrecfinib in Pafients with ROS1+ Non-Small Cell Lung Cancer (NSCLC): Updated Safety Analysis From the Phase 2 TRUST-I and TRUST-II Studies
2026 · Amanda Herrmann, Jorge J. Nieva, et al. · Journal of Thoracic Oncology
Arterial and venous thromboembolic events in ALK - and ROS1 -positive non–small cell lung cancer (NSCLC): A multicenter real-world analysis.
2026 · Kim Abbegail Tan Aldecoa, Ibrahim Azar, et al. · Journal of Clinical Oncology
PP01.63: Surgery in Previously Unresectable Stage IV Driver Mutation Lung Adenocarcinoma Patients After Targeted Therapy: A Single Center Experience
2026 · Ronak Naik, Carlin Lee, et al. · Journal of Thoracic Oncology
OA01.02: Efficacy and Safety of Zenocutuzumab, a HER2/HER3 Bispecific Antibody, in Treatment-Naive, Advanced NRG1+ NSCLC: Updated Analysis from the Ongoing Phase 2 eNRGy Trial
2026 · Stephen V. Liu, Muskan Agarwal, et al. · Journal of Thoracic Oncology
PP01.32: Zidesamtinib in Patients with Advanced/Metastatic ROS1-Positive (ROS1+) Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Tyrosine Kinase Inhibitors (TKI): Pivotal Efficacy and Safety Data from the Phase 1/2 ARROS-1 Trial
2026 · Stephen V. Liu, Alexander E. Drilon, et al. · Journal of Thoracic Oncology
Assessment of real-world surveillance strategies for patients undergoing systemic therapy for brain metastases
2026 · Britney Weng, Caressa Hui, et al. · Frontiers in Oncology
PDF
Supplementary Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
2026 · Sarah Waliany, Alissa J. Cooper, et al.
Table S3 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
2026 · Sarah Waliany, Alissa J. Cooper, et al.
Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
2026 · Sarah Waliany, Alissa J. Cooper, et al.
Works count: 18
Citation count: 16
H-index: 2
I10-index:
Year
Topic
Type